DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: Community Center
Online support, community stories, financial assistance
Pat Jordan – Amyloidosis Patient Story
When Pat Jordan, 65, was officially diagnosed with hereditary ATTR (hATTR) amyloidosis in May 2016, her first thought was, “Well, now I know how I’m going to die.” Her second response, however, was one of relief, because the diagnosis finally put a name to the various medical problems she had been experiencing over the past 20 years.
There are many forms of amyloidosis, some of which are similar to blood cancers. hATTR amyloidosis is not cancer, but it is a debilitating, life-threatening disorder caused by a gene mutation that affects transthyretin (TTR), a protein made primarily in the liver that helps carry substances like thyroid hormone and vitamin A throughout the body. hATTR amyloidosis can affect the peripheral nervous system, the autonomic nervous system and the heart, and because there is currently no cure, it’s considered a terminal disease.
Related Content
-
educationCardiac Amyloidosis: From Clinical Suspicion to Morphological DiagnosisAmyloidosis is a heterogeneous group of ...
-
educationAA AmyloidosisAA amyloidosis, or secondary amyloidosis...
-
educationRecent Advances in the Management of AL AmyloidosisImmunoglobulin light chain (AL) amyloido...
-
people & placesRaymond L. Comenzo, MDDr. Raymond Comenzo received his medic...
-
people & placesAngelo Maiolino, MD, PhDAngelo Maiolino is an Associate Professo...
-
educationWhat to Expect on Your hATTR Amyloidosis JourneyFamily History Given the hereditary (ru...
-
videos & visualsAmyloidosis Diagnosis, Treatment Concepts, and Future – Dr. Mark Pepyshttps://www.youtube.com/watch?v=31xThMYI...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.